Drug intelligence / Profile preview

MBX-700

Development stage: Preclinical
Lead developer: Microbiotix
Modality: Small Molecules

Overview

MBX-700 is an investigational small‑molecule non‑nucleoside inhibitor of the hepatitis C virus (HCV) NS5B RNA‑dependent RNA polymerase, originally developed by Merck as part of its direct‑acting antiviral portfolio for chronic HCV infection.[5][10] By binding to an allosteric site on NS5B, it was designed to block viral RNA synthesis and replication, thereby suppressing HCV viral load, typically as part of combination regimens with other antivirals.[5][10] Development of MBX-700 did not progress to late‑stage clinical trials and its global R&D status is reported as pending.[5]

Targets

NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on MBX-700.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBX-700.

Explore the full profile